ACTâs Dr. Robert Lanza to Receive the Il Leone di San Marco Award in Medicine
September 24 2013 - 8:30AM
Business Wire
Past honorees in other fields have included
Dion, Susan Lucci, Tony Danza, Paul Giamatti, Paul Sorvino and Rudy
Giuliani
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in
the field of regenerative medicine, announced today that the
companyâs Chief Scientific Officer, Robert Lanza, MD, has been
nominated to receive the prestigious Il Leone di San Marco award in
Medicine. For thirty-three years, the Italian Heritage and Culture
Committee of the Bronx and Westchester has acknowledged outstanding
Americans in fields such as the Performing Arts, Entertainment,
Medicine, Journalism, Literature, Playwriting, Government, Science,
Academia or Business. Past honorees have included Stanley Tucci,
Paul Giamatti, Paul Sorvino, Danny Aiello, Armand Assante, Tony
Danza, Susan Lucci, Dion DiMucci, Phil Ramone, Bart Giamatti, and
Rudy Giuliani.
Dr. Lanza is one of only four people who will receive this
yearâs Il Leone di San Marco Award for their âmany talents and
great accomplishmentsâ who represent the best in Italian-American
culture. The other three honorees are Regis Philbin
(Entertainment), Roma Torre (Theater Criticism), and Michael
Gargiulo (Broadcast Journalism). The award in Medicine will be
presented to Dr. Lanza on Sunday September 29th at the Davenport
Club on Long Island Sound, New York. In addition to the award
presentation, there will be musical performances by Giada Valenti,
Eugene Ruffolo, and Luigi Moneta & Gayle Scott.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company
applying cellular technology in the field of regenerative medicine.
For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, the relevance and applicability of clinical
trials in animals to studying the effect of products in humans,
future growth in animal and human research and development
programs, potential new applications of and expanded indications
covering our technology, the effects of donorless sources of stem
cells on potency and the risk of communicable diseases in the
manufacturing context, the existence and size of potential or
existing market opportunities for the company, the effect of the
companyâs products on the medical needs and quality of life of
pets, and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements
that are not statements of historical fact (including statements
containing the words âwill,â âbelieves,â âplans,â
âanticipates,â âexpects,â âestimates,â and similar
expressions) should also be considered to be forward-looking
statements. There are a number of important factors that could
cause actual results or events to differ materially from those
indicated by such forward-looking statements, including: limited
operating history, need for and limited sources of future capital,
failures or delays in obtaining regulatory approval of products,
risks inherent in the development and commercialization of
potential products, reliance on new and unproven technology in the
development of products, protection of our intellectual property,
and economic conditions generally. Additional information on
potential factors that could affect our results and other risks and
uncertainties are detailed from time to time in the companyâs
periodic reports, including the Quarterly Report on Form 10-Q for
the three months ended June 30, 2013. Forward-looking statements
are based on the beliefs, opinions, and expectations of the
companyâs management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of the companyâs
management at the time they are made, and the company does not
assume any obligation to update its forward-looking statements if
those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Companyâs
clinical trials will be successful.
Investors:CEOcast, Inc.James Young, 212-732-4300orPress:Russo
PartnersDavid Schull, 212-845-4271